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iNtroductioN
Colorectal cancer accounts for 9.7% of all cancers worldwide 
(excluding non-melanotic skin cancer). It is the second most 
common cancer in Europe and third most common cancer in 
the world.1 It is far more common in the Western world with age 
standardised incidence rates being highest in Europe and North 
America (Table 1) and lowest in Africa and Central America.1
There is variation in the trends in incidence and mortality of 
colorectal cancer in different countries with three main patterns 
being observed: 
•	 Increase	in	incidence	and	mortality	is	being	seen	in	rapidly	
transitioning regions such as Eastern Europe, Asia and 
South America; 
•	 Increase	in	incidence	with	a	decrease	in	mortality	is	
being seen in some European countries such as Denmark, 
Sweden, United Kingdom and Malta amongst others as well 
as Canada and Singapore; 
•	 In	countries	such	as	the	United	States,	Japan	and	other	
Western countries both incidence and mortality have 
stabilised or have even started to decline.2
Colorectal cancer is associated with a number of modifiable 
risk factors including diets rich in animal fat and protein, 
obesity and lack of physical activity, smoking and excessive 
alcohol consumption. Inherited conditions such as familial 
adenomatous polyposis (FAP) as well as a personal history of 
inflammatory bowel diseases3 are associated with a high risk of 
developing colorectal cancer. The latter risk conditions account 
for only a small proportion of all colorectal cancer cases.    
A reduction in colorectal cancer incidence and mortality 
is achievable through a number of measures which include 
primary prevention through improved nutrition and increased 
physical activity, and organised population-based cancer 
screening programmes. New and advanced treatments are also 
contributing towards improvements in the outcomes of colorectal 
cancer care. There are wide variations worldwide in the state of 
implementation of colorectal screening with countries such as the 
United States and Japan having organised screening programmes 
since the 1990s.4 On the other hand, by 2008, only 19 out of the 
27 EU countries had or were developing a screening programme.5 
By 2015, this implementation figure has gone up to 24 out of 28 
EU countries.4 However, to date there are still several countries 
worldwide with no organised screening programme in place 
despite having a high incidence and mortality from the disease.4 
abstract
Colorectal cancer is the second most common cancer in 
Malta. On average, between 2012-2014, 259 persons have 
been diagnosed with colorectal cancer and 110 persons 
died each year. It is a disease of the Western world. The 
need to target colorectal cancer from prevention through 
physical exercise and healthy eating, to earlier diagnosis and 
treatment, through organised screening programmes and 
fast track referral systems and advanced treatment protocols 
is crucial to reduce incidence and improve survival. 
Table 1: Estimated incidence in specific world regions, both sexes, 20121
Population Numbers Crude Rate ASR (W)
World 1360602 19.3 17.2
Africa 41105 3.8 6.3
Central America 11601 7.2 8.0
South America 67464 16.8 15.7
Morthern America 158169 45.1 26.1
Asia 607182 14.3 13.7
Central and Eastern Europe 139856 47.6 26.6
Northern Europe 65162 65.0 30.4
Southers Europe 105009 66.7 31.1
Malta 268 63.9 31.9
Western Europe 137109 72.3 31.4
+ (age standardised rates using the world standard population)
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EPidEmiologY oF colorEctal caNcEr iN malta
colorEctal caNcEr iNcidENcE
Colorectal cancer is the second commonest cancer for Malta 
in both genders combined following breast cancer. On average, 
146 males and 113 females (3 year average of 2012-2014) are 
diagnosed each year with colorectal cancer. The incidence of 
colorectal cancer increases with age (Figure 1) and age-specific 
incidence rates in males are much higher than those in females 
for most age groups.6 
The standardised incidence rate of colorectal cancer in Malta 
has remained relatively stable in females (Figure 2) but seems to 
show a rising trend in males. Incidence rates in Malta in both males 
and females are lower than the EU average (Malta: M: 42.1, F: 35.2; 
EU-27 average: M: 59.0, F: 36.1 in 2012 per 100,000 pop (ESP).7 
colorEctal caNcEr mortalitY 
mortalitY
On average there are 61 male deaths and 49 female deaths due 
to colorectal cancer each year (average of 2012-2014). Colorectal 
cancer is the second most common cause of cancer death in 
both sexes combined following lung cancer. Average age at death 
for both genders is 73 years (2012-2014). The age standardised 
mortality rate has remained relatively stable in males over 
the past years (Figure 3) but is showing a downward trend in 
females.6 Mortality rates in Malta in both males and females are 
slightly above the EU average (Malta: M: 23.9, F: 15.9; EU-27 
average: M: 23.8, F: 14.2 in 2012 per 100,000 pop (ESP)).7
  
survival
The one-year and 5-year relative survival for patients with 
invasive colon cancer who were diagnosed between the years 
2000-2007 was 77.6 and 57.0 respectively in Europe.8 Malta 
Figure 1. Yearly age-specific incidence rate for colorectal cancer 
(average of 2012-2014), by gender6 
Figure 2. Trends in standardised incidence rate (European Standard Population) 
in males and females in Malta6 
observed one of the highest increases in colon cancer 5-year 
relative survival from 53% for patients diagnosed between 
1999-2001 to 61% in patients diagnosed with colon cancer in 
2005-2007.8 As presented in the tables below, one-year relative 
survival of patients with rectal cancer is higher than those with 
colon cancer in all regions. However, the same does not always 
apply for the 5-year relative survival. In Malta, between the 
periods 1999-2001 and 2005-2007, the 5-year relative survival 
for patients with rectal cancer fell from 60% to 50% (European 
average increased by 6 percentage points to 58%).8
sErvicEs For thE maNagEmENt oF PatiENts 
with colorEctal caNcEr iN malta
Prior to the introduction of the colorectal screening 
programme in Malta in November 2012, screening for 
colorectal cancer by faecal occult blood tests (FOBT) and 
other means was only performed on an opportunistic basis 
and activity rates were very low. Only 2.6% of persons aged 
between 50 and 74 years interviewed in the European Health 
Interview Survey carried out in 2008 reported as having had a 
FOBT in the previous two years.9
The National Colorectal Cancer Screening programme was 
launched in November 2012. During its first screening cycle, 
persons aged between 60-64 years were invited to undergo 
colorectal cancer screening. The colorectal cancer screening 
programme is now in its second cycle and persons aged 55 to 
66 years are invited to undertake an iFOBT (immunochemical-
faecal occult blood test) every 2 years. Clients that obtain 
a positive iFOBT result are referred for a colonoscopy. The 
aim is to eventually reach the age cohorts 50 to 74 years 
recommended in the EU Council Recommendation of 2003 on 
Cancer Screening.10
Apart from the screening route, patients can also enter the 
colorectal cancer care pathway from the symptomatic route. 
A number of measures are being planned and introduced to 
ensure that patients with suspicious signs and symptoms gain 
access to specialist care in hospital in the shortest time possible. 
One of these measures involves the introduction of a fast-
track referral system. A pilot system relating to the fast-track 
referral system for colorectal cancer was introduced in early 
2016 whereby participating family physicians can complete 
an electronic referral form that has been specifically designed 
for this purpose. A surgeon with a special interest in colorectal 
surgery vets these referrals. When the indication for a fast-track 
colorEctal caNcEr 
is thE sEcoNd 
commoNEst caNcEr 
For malta iN both 
gENdErs combiNEd 
FollowiNg brEast caNcEr
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a Pilot sYstEm rElatiNg to thE 
Fast-tracK rEFErral sYstEm For 
colorEctal caNcEr was iNtroducEd 
iN EarlY 2016 whErEbY ParticiPatiNg 
FamilY PhYsiciaNs caN comPlEtE aN 
ElEctroNic rEFErral Form that has bEEN 
sPEciFicallY dEsigNEd For this PurPosE
referral is confirmed, the family physician is instructed on how 
best to prepare their patient and an expedited appointment for a 
colonoscopy is given.
Measures are also being planned to ensure continuity 
and seamless care for patients navigating the cancer pathway 
from diagnosis to palliative care and survivorship. The aims 
are to improve patients’ experience and outcomes and also 
to assist patients during this challenging journey. These 
include the planned and incremental introduction of cancer 
care pathway navigators. These navigators will most often be 
nursing professionals and they will be appointed to act as care-
coordinators for patients with various cancers. Navigators will 
be assigned to different groups of cancer patients so that they 
will be able to develop specific expertise in assisting patients 
with similar conditions.
The diagnostic and treatment plan of patients suspected 
or diagnosed with colorectal cancer is discussed during 
multidisciplinary team (MDT) meetings which are held 
once every fortnight at Mater Dei Hospital. Support for the 
operations of these MDTs will be reinforced to improve 
their effectiveness and to ensure inclusivity for all patients 
diagnosed with colorectal cancer. Plans also envisage that 
the MDTs will eventually assume the role of a tumour 
management group which will have the responsibility of 
developing and overseeing the implementation of relevant 
national care guidelines and monitor and evaluate selected 
performance outcome indicators. 
discussioN aNd coNclusioN
There is large variation in trends in mortality from colorectal 
cancer in the different European countries, with an average 
reduction in mortality in EU 27 falling by 13% in men and 27% 
in women between 1989 and 2011.11 Countries including the 
United Kingdom, Austria, Germany and Ireland amongst others 
showed major reductions in mortality while other countries 
especially central European countries showed either a small 
decline or no decline at all.11  In Malta the overall mean change 
in mortality in females fell by 15.9% while in males it increased 
by 5.2% from between 1989 and 2011.11 Implementation of and 
participation rates in national screening programmes varies 
considerably between countries and this is considered to be an 
important factor in reducing mortality.12  
The need to target colorectal cancer from prevention, 
through to earlier diagnosis and advanced treatment protocols 
is key to improved survival3 and requires financial resources and 
well planned cancer strategies.    
Figure 3. Trends in standardised mortality rate (European Standard Population) 
in males and females in Malta.6 
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Table 2: 1-year and 5-year relative survival for adult patients with 
invasive colon cancer diagnosed in 2000-20078
Region/Country 1 year 5 year
Northern Europe 79.3 (78.9-79.6) 59.0 (58.5-59.5)
Ireland and UK 72.6 (72.4-72.8) 51.8 (51.5-52.1)
Central Europe 80.5 (80.3-80.7) 60.5 (60.2-60.8)
Southern Europe 78.6 (78.4-78.9) 58.5 (58.1-58.8)
Malta 74.9 (72.0-78.0) 58.1 (53.7-62.7)
Eastern Europe 69.7 (69.4-70.1) 49.4 (48.9-49.8)
Table 3: 1-year and 5-year relative survival for adult patients with 
invasive rectum cancer diagnosed in 2000-20078
Region/Country 1 year 5 year
Northern Europe 83.4 (83.0-83.8) 59.5 (58.9-60.2)
Ireland and UK 78.5 (78.2-78.7) 53.7 (53.3-54.1)
Central Europe 83.7 (83.5-84.0) 60.1 (59.7-60.5)
Southern Europe 80.4 (80.1-80.7) 55.4 (54.9-55.9)
Malta 82.1 (78.5-85.8) 52.8 (47.0-59.3)
Eastern Europe 72.4 (72.0-72.8) 44.6 (44.1-45.1)
Cancer control services require a comprehensive approach 
for the planning, acquisition and governance of the necessary 
organisational, human, technological and financial resources 
for the sustainability and further development of the services 
needed to meet the increasing demand and the dynamic and 
evolving domains of cancer care. A new National Cancer Plan 
for Malta is currently being collated and this strategy will include 
several measures aimed at generating quality improvements 
at the multiple different phases of the cancer care pathways. 
Measures will include generic upgrades that will affect all 
cancer patients such as the implementation of a comprehensive 
ICT infrastructure that will closely document an individual 
patient’s trajectory, improve connectivity between different care 
providers and allow the generation of more timely and detailed 
cancer intelligence. The new National Cancer Plan will also 
include specific developments that will target the accessibility of 
increasingly more advanced levels of expertise and technology 
(including cancer care medicines) for specific cancer groups. 
In 2015 the Ministry for Health set up the Cancer Care 
Pathways Directorate. The aim of this directorate is to develop 
individualized pathways of excellence in cancer care where the 
journey of both patients and their families is facilitated in a safe 
and integrated manner through the provision of holistic care. 
It also supports, recommends and implements changes within 
cancer services to ensure high quality services that are delivered 
in a timely manner. 
Support for the patients and their families during this time is 
an important factor that helps people cope with this challenging 
condition. The Malta ColoRectal Cancer Awareness Group 
(MCRCAG - http://www.crc.org.mt/GetSupport) has been set 
up in February of this year with the aim of creating awareness 
and education about colorectal cancer as well as support to the 
patients and their families and caregivers.
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